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A B S T R A C T
Background
For tuberculosis treatment, policies have been introduced to encourage adherence to treatment regimens. One such policy is directly
observed therapy (DOT), which involves people directly observing patients taking their antituberculous drugs.
Objectives
To compare DOT with self administration of treatment or different DOT options for people requiring treatment for clinically active
tuberculosis or prevention of active disease.
Search strategy
In May 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007,
Issue 2), MEDLINE, EMBASE, LILACS, and mRCT. We also checked article reference lists and contacted relevant researchers and
organizations.
Selection criteria
Randomized and quasi-randomized controlled trials comparing a health worker, family member, or community volunteer routinely
observing people taking antituberculous drugs compared with routine self administration of treatment at home. We include people
requiring treatment for clinically active tuberculosis or medication for preventing active disease.
Data collection and analysis
Both authors independently assessed trial methodological quality and extracted data. Data were analysed using relative risks (RR) with
95% confidence intervals (CI) and the fixed-effect model when there was no statistically significant heterogeneity (chi square P > 0.1).
Trials of drug users were analysed separately.
Main results
Eleven trials with 5609 participants met the inclusion criteria. No statistically significant difference was detected between DOT and
self administration in terms of cure (RR 1.02, 95% CI 0.86 to 1.21, random-effects model; 1603 participants, 4 trials), with similar
results for cure plus completion of treatment. When stratified by location, DOT provided at home compared with DOT provided at
clinic suggests a possible small advantage with home-based DOT for cure (RR 1.10, 95% CI 1.02 to 1.18; 1365 participants, 3 trials).
There was no significant difference detected in clinical outcomes between DOT at a clinic versus by a family member or community
health worker (2 trials), or for DOT provided by a family member versus a community health worker (1326 participants, 1 trial). Two
small trials of tuberculosis prophylaxis in intravenous drugs users found no statistically significant difference between DOT and self
administration (199 participants, 1 trial) or a choice of location for DOT for completion of treatment (108 participants, 1 trial).
Authors’ conclusions
The results of randomized controlled trials conducted in low-, middle-, and high-income countries provide no assurance that DOT
compared with self administration of treatment has any quantitatively important effect on cure or treatment completion in people
receiving treatment for tuberculosis.
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P L A I N L A N G U A G E S U M M A R Y
Directly observing people taking their tuberculosis drugs did not improve the cure rate compared with people without direct
monitoring of treatment
Tuberculosis is a very serious health problem with two million people dying each year, mostly in low-income countries. Effective drugs
for tuberculosis have been available since the 1940s, but the problem still abounds. People with tuberculosis need to take the drugs for
at least six months, but many do not complete their course of treatment. For this reason, services for people with tuberculosis often use
different approaches to encourage people to complete their course of treatment. This review found no evidence that direct observation
by health workers, family members, or community members of people taking their medication showed better cure rates that people
having self administered treatment. The intervention is expensive to implement, and there appears to be no sound reason to advocate
its routine use until we better understand the situations in which it may be beneficial.
B A C K G R O U N D
Adherence in tuberculosis management
Effective drugs for tuberculosis have been available since the 1940s,
but two million people continue to die each year, mostly in low-
income countries (Dye 1999; Netto 1999). People with tubercu-
losis require treatment for at least six to eight months. Many find
it difficult to complete their course of treatment and this serves as
a major constraint to eradicating the disease (Fox 1958; Adding-
ton 1979; Cuneo 1989). Poor adherence to treatment can lead to
prolonged infectiousness, drug resistance, relapse of tuberculosis,
or even death. Incomplete treatment thus poses a serious risk for
the individual as well as the community.
There are three groups of people for whom adherence is impor-
tant: people under evaluation for suspected tuberculosis (to ensure
they complete the diagnostic regimen or start treatment); people
receiving prophylaxis (preventive therapy), where antituberculous
drugs are given to people exposed to tuberculosis or thought to
be at particular risk; and people with diagnosed tuberculosis in
whom completion of treatment helps ensure cure.
Adherence to a tuberculosis treatment programme requires acces-
sible and appropriate health care. People need to be diagnosed cor-
rectly, provided with information about their disease and the need
for completion of treatment, and suppliedwith appropriate outpa-
tient drugs. But evenwhere these services are available, people may
not adhere to the intended regimen. Healthcare providers have
responded by developing a variety of specific measures to improve
adherence (Cuneo 1989; CDC 1993; Sbarbaro 1994). These in-
terventions are aimed at influencing the behaviour of healthcare
personnel, the organization of the service, or the behaviour of the
person with suspected or confirmed tuberculosis. Originally we
included all these interventions in one Cochrane Review, but this
approach did not allow us to consider the particulars of each of
the following interventions, and why in one set of circumstances
it may be effective and another it may not. This Cochrane Review
is one of several planned or in progress to evaluate each type of
intervention:
• Directly observed therapy (DOT): an appointed agent (health
worker, community volunteer, family member) directly moni-
tors people swallowing their antituberculous drugs (this review).
• Staff motivation and supervision: training and management
processes that aim to improve how providers care for people
with tuberculosis.
• Reminder systems and late patient tracers in the diagnosis and
management of tuberculosis: routinely reminding patients to
keep an appointment and actions taken when patients fail to
keep an appointment (Liu 2007).
• Education and counselling for promoting adherence to the
treatment of active tuberculosis: provision of information or
one-to-one or group counseling about tuberculosis and the need
to attend for treatment (M’Imunya 2007).
• Incentives and reimbursements: money or cash in kind to reim-
burse expenses of attending services, or to improve the attrac-
tiveness of visiting the service.
• Contracts: written or verbal agreements to return for an ap-
pointment or course of treatment (Bosch-Capblanch 2007).
• Peer assistance: people from the same social grouphelping some-
one with tuberculosis return to the health service by prompting
or accompanying them.
DOT
DOT seeks to improve the adherence of people to tuberculosis
treatment through health workers, family members, or commu-
nitymembers directly observing them taking their antituberculous
drugs. This approach was first adopted in studies inMadras, India,
and Hong Kong as early as the 1960s (Bayer 1995), and a num-
ber of specialists now widely recommend DOT for the control
of tuberculosis (Bass 1994; Maher 1997; Chaulk 1998; Enarson
2000). Indeed, Frieden and Sbarbaro state that it is essential and
that it prevents relapse occurring and drug resistance developing
(Frieden 2007).
The advantages of DOT are that people can be closely monitored
and that there is a social process with peer pressure that may im-
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prove adherence. On the other hand, the disadvantages associ-
ated with DOT are that it moves away from adherence models of
communication with cooperation between patient and provider
back to a traditional medical approach with the patient as the pas-
sive recipient of advice and treatment (Donovan 1992; Sumartojo
1993); resource implications for such a policy are substantial, par-
ticularly in low-income and middle-income countries where the
case load is high; and it may make adherence worse if it is rigidly
applied in an authoritarian setting or where people are expected
to travel considerable distances to have their treatment supervised
Programmes that include DOT
Over the years DOT has come to mean much more than the
supervised swallowing of drugs, causing considerable confusion.
In the USA, DOT programmes are complex and consist of several
components including social support, housing, food tokens, and
jail for recalcitrant people (ATS 1992; Volmink 2000b).
The World Health Organization (WHO) promotes another ver-
sion of DOT called ’directly observed therapy, short course’
(DOTS). This is a comprehensive tuberculosis management pro-
gramme that focuses on low-income countries. DOTS is a five-el-
ement strategy for the control of tuberculosis that consists of polit-
ical commitment, improved laboratory analysis, direct patient ob-
servation while swallowing each dose of medication, a drug supply
that provides for the correct complete short course antituberculous
drug combination for free, and a reporting system that documents
the progress in curing the patient (WHO 1997).
The WHO believes that direct observation is a key element for
the success of DOTS and has retained it in more recent definitions
of the DOTS strategy, although their documentation has clearly
taken into account criticisms of their blanket policy. For exam-
ple, the WHO states that the third component of their expanded
strategic framework is “standardized short-course chemotherapy to
all cases of TB [tuberculosis] under proper case-management con-
ditions including direct observation of treatment” (WHO 2002).
The 2004 progress reportmentions direct observation for “at least”
the first two months of treatment (WHO 2004). Even so, how
this is interpreted in countries varies, and direct observation by a
health worker remains national policy in China, for example.
In contrast, we have previously suggested that the benefits associ-
ated with DOT programmes found in observational studies may
be attributable to simultaneous inputs rather than direct observa-
tion specifically (Volmink 1997a). An informed debate is impor-
tant because direct observation has considerable resource impli-
cations; it therefore important to determine how important this
intervention is for improving adherence to tuberculosis treatment
and ensuring cure. Since our initial Cochrane Review (Volmink
1997b), which documented the absence of randomized controlled
trials of DOT, several trials have been conducted aimed at dis-
aggregating the effects of this specific intervention from those of
accompanying inputs, and they are included in this review update.
Not only is there a debate about whether DOT is effective, there is
also a debate about who should provide this. This may be contin-
gent practically on an individual’s circumstances, but the special-
ists are divided in their recommendations: some consider family
members can help, whereas others regard family observation as a
“seductive but risky concept” (Frieden 2007). We therefore also
summarize trials comparing DOT through different providers and
settings.
O B J E C T I V E S
To compare DOT with self administration of treatment or dif-
ferent DOT options for people requiring treatment for clinically
active tuberculosis or prevention of active disease.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
People requiring treatment for clinically active tuberculosis or
medication for preventing active disease (prophylaxis or preven-
tive therapy).
Types of intervention
Intervention
Health worker, familymember, or community volunteer routinely
observes participants taking their antituberculous drugs.
Control
Routine self administration of treatment at home, with intermit-
tent clinic visits for drugs with or without treatment adherence
checks.
Where researchers explored different methods of implementing
direct observation, the experimental method was allocated to the
intervention group and the standard method to the control.
Types of outcome measures
Primary
• Cure.
• Completion of treatment.
• Development of clinical tuberculosis (in trials of drug prophy-
laxis).
Secondary
Keeping outpatient appointments.
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S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Infectious Diseases Group methods used in
reviews.
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Databases
We searched the following databases using the search terms and
strategy described in Table 01: Cochrane Infectious Diseases
Group Specialized Register (May 2007); Cochrane Central
Register of Controlled Trials (CENTRAL), published in The
Cochrane Library (2007, Issue 2); MEDLINE (1966 to May
2007); EMBASE (1974 to May 2007); and LILACS (1982 to
May 2007). We also searched the metaRegister of Controlled
Trials (mRCT) using ’tuberculosis AND DOT*’ (May 2007).
Researchers and organizations
For unpublished and ongoing trials, we contacted individual
researchers working in the field and the following organizations:
World Health Organization (1997 and 2004), the International
Union Against Tuberculosis and Lung Disease (IUATLD)
(1997), and the Centers for Disease Control and Prevention
(1997).
Reference lists
We also checked the reference lists of all studies identified by the
above methods.
M E T H O D S O F T H E R E V I E W
Trial selection
Both authors independently applied the inclusion criteria to all
identified trials. We used the titles and abstracts of the identified
citations to exclude trials that clearly did not meet the inclusion
criteria. If either author judged that the trial might be eligible for
inclusion, we obtained the full paper. We independently screened
the full articles of selected trials to confirm eligibility and resolved
any disagreements by discussion.
Assessment of methodological quality
We independently evaluated the methodological quality of each
trial, classifying the generation of allocation sequence and
concealment of allocation as adequate, inadequate, or unclear
according to Juni 2001. We classified blinding as adequate if steps
were taken to ensure the people recording the main outcome of
the study were blind to the assigned interventions and inadequate
if this was not the case or if there was no mention of attempts
to blind the observers. We assessed completeness of follow up as
adequate if 90% or more, inadequate if less than 90%, or unclear
if not mentioned.
Data extraction
We independently extracted the data and checked whether
authors had conducted an intention-to-treat analysis. Trialistswere
contacted to supply missing information and to clarify issues. We
resolved discrepancies through discussion.
Data analysis
We used Review Manager 4.2 to analyse the data, using relative
risk (RR) with 95% confidence intervals (CI) to assess estimates
of effect. We used the fixed-effect model when there was no
statistically significant heterogeneity (chi square P > 0.1).
D E S C R I P T I O N O F S T U D I E S
Eleven trials with 5609 participants met the inclusion criteria (see
’Characteristics of included studies’). Twelve studies that initially
seemed to fit the inclusion criteria were eventually excluded from
our review; reasons for these decisions are provided in the ’Char-
acteristics of excluded studies’.
Eight of the 11 trials were conducted in low-income and middle-
income countries and evaluated DOT for treating people with ac-
tive tuberculosis: Pakistan (Walley 2001); South Africa (Zwaren-
stein 1998; Zwarenstein 2000); Tanzania (Lwilla 2003; Wandwalo
2004); Nepal (Newell 2006); Thailand (Kamolratanakul 1999);
and Swaziland (Wright 2004). Three trials were in high-income
countries: one in Australia (MacIntyre 2003); and two in the USA
that examined prophylaxis in intravenous drug users (Chaisson
2001; Malotte 2001). Two trials were cluster randomized (Lwilla
2003; Newell 2006). One trial used a quasi-random method of
allocation (MacIntyre 2003).
Services for general populations
DOT versus self administration of treatment
Five trials compared DOT with self administration of treatment.
There is some overlap of data in two of these trial reports, but we
have taken this into account in the analyses: Zwarenstein 1998
combined data from two communities in which trials compared
direct observation by nurses at clinics with self administration of
treatment, while Zwarenstein 2000 described data from one of
these trials that had three arms of direct observation by nurses,
lay health workers, and self administration. Kamolratanakul 1999
allowed participants to choose between DOT by a health worker,
community leader, or family member; most chose the latter. Wal-
ley 2001 comparedDOT by a health worker or community health
worker with DOT by a family member and with self administra-
tion of treatment. MacIntyre 2003 evaluated DOT by a family
member.
Alternative DOT delivery options
A cluster-randomized trial fromTanzania (Lwilla 2003) compared
a community health worker observing people at home with DOT
at a health facility. Three trials comparedDOTby a familymember
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with either DOTby a health worker at a health facility (Wandwalo
2004) or DOT by a community health worker (Wright 2004;
Newell 2006).
Services for intravenous drug users
Two trials from the USA evaluated DOT in drug users on pro-
phylaxis for latent tuberculosis (Chaisson 2001; Malotte 2001).
Malotte 2001 studied intravenous and crack cocaine users, and
compared DOT by an outreach worker at a site chosen by the
participant (with or without a US$5 at each visit) with DOT at
a community clinic with a US$5 at each visit. Chaisson 2001 in-
volved intravenous drug users, and studied DOT by an outreach
nurse with self administration either with monthly peer support
or monthly clinic visits.
Outcomes
The numbers of people cured, cured and completed treatment,
or completed treatment were the main outcomes assessed in the
included trials.
Adjustment for clustering
Both cluster trials adjusted for clustering appropriately: standard
error of the coefficients for clustering on units corrected using the
Huber-White-Sandwich method (Lwilla 2003); and, in Newell
2006, using the coefficient of variation between clusters.
M E T H O D O L O G I C A L Q U A L I T Y
See Table 02 for a summary of the assessment.
Generation of allocation sequence
Seven trials used adequate methods − computer-generated ran-
dom sequences (Zwarenstein 1998; Zwarenstein 2000; Walley
2001; Chaisson 2001), a random-number table (Kamolratanakul
1999), coin tossing (Wandwalo 2004), and random draws of pa-
per from a basket (Newell 2006). One trial used alternate allo-
cation, an inadequate method (MacIntyre 2003). The remaining
trial reports did not provide information (Malotte 2001; Lwilla
2003; Wright 2004).
Allocation concealment
Four trials employed adequate methods for concealing alloca-
tion (Zwarenstein 1998; Zwarenstein 2000; Walley 2001; Malotte
2001). Allocation concealment was unclear in three trials (Chais-
son 2001; Lwilla 2003; Wright 2004) and not used in the re-
maining trials (MacIntyre 2003; Kamolratanakul 1999; Wand-
walo 2004; Newell 2006).
Blinding
Outcome assessment was blind in only four trials (Walley 2001;
MacIntyre 2003; Wright 2004; Newell 2006).
Completeness of follow up
In two trials, more than 10% of participants were excluded from
the analysis (Chaisson 2001; Lwilla 2003). A further four trials
did not provide sufficient information to assess this aspect of study
quality (Zwarenstein 2000; Malotte 2001; Walley 2001; MacIn-
tyre 2003). In the rest of the trials follow up was adequate.
R E S U L T S
(1) Services for general public
DOT versus self administration of treatment
Treatment outcomes were similar among participants in the DOT
and self administration of treatment arms. There was no statisti-
cally significant difference between the interventions for the num-
ber of people cured (1603 participants, 4 trials, Analysis 01.01),
cured or completed treatment (1603 participants, 4 trials, Analysis
01.02), or completed treatment (173 participants, 1 trial, Analysis
01.03). There was significant heterogeneity between the trials for
cure (chi squared 8.41; df = 3), but the point estimate of the RR
was close to one, and no difference was demonstrated with either
fixed-effect or random-effects models (Analysis 01.01).
We explored whether different effect sizes were associated with
home-based and clinic-based DOT. Effect size was similar in the
two groups (Analyses 02.01 and .02). Home-based DOT was
strongly influenced by the trial from Thailand (Kamolratanakul
1999), and there was a statistically significant improvement in
cure, but the difference was small (RR 1.10, 95% CI 1.02 to 1.18;
1365 participants, 3 trials, Analysis 02.01).
DOT: family member or community health worker versus at
clinic
Wandwalo 2004 found cure or treatment completion to be similar
for those observed by a family member compared with a health
worker (587 participants, 1 trial, Analysis 03.01). A cluster-ran-
domized trial, Lwilla 2003, which evaluated DOT by a commu-
nity health worker, found no difference for sputum conversion at
two months (OR 0.62, 95% CI 0.23 to 1.71) or cure at the end of
treatment (OR 1.58, 95% CI 0.32 to 7.88; trial authors adjusted
for design effects).
DOT: family member versus by a community health worker
Wright 2004 found no statistically significant difference in the
number of people cured orwho completed treatment (1326 partic-
ipants, Analysis 04.01). A cluster-randomized trial, Newell 2006,
which compared community-based DOT by a community health
worker or village health worker with family-based DOT, found no
statistically significant difference in success rates (cure and treat-
ment completion) (85% vs 89%; OR 0.67, 95% CI 0.41 to 1.10;
trial authors adjusted for design effects).
(2) Services for intravenous drug users
Chaisson 2001 found no statistically difference in the number of
people who completed twice-weekly clinic-based DOT and those
on daily self administration of treatment (199 participants, Anal-
ysis 05.01). For participants receiving prophylaxis, Malotte 2001
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studied people receiving prophylaxis and found no statistically sig-
nificant difference in the number who completed treatment be-
tween those allowed to choose their DOT location and those re-
ceiving DOT at a community clinic (108 participants, Analysis
06.01).
D I S C U S S I O N
Direct observation of people taking their antituberculous drugs
is widely advocated and forms part of the World Health Organi-
zation’s ’directly observed therapy, short course’ (DOTS) strategy.
While this strategy includes a number of useful components, the
available evidence does not provide strong support for the routine
adoption of direct observation in favour of self administration of
treatment either for people with active tuberculosis or those with
latent tuberculosis requiring prophylaxis. There is also no evidence
that one form of direct observation is better than another: direct,
randomized comparisons between clinic-based DOT and com-
munity-based DOT did not demonstrate a difference; and, within
community-based DOT, comparisons between DOT provided by
a family member versus a community health worker had similar
outcomes.
Given the prevailing support for DOT-based programmes, these
findings are important. We have previously suggested that the
benefits associated with DOT programmes in observational stud-
ies may be attributable to simultaneous interventions rather than
direct observation being the key adherence-promoting strategy
(Volmink 2000b). A qualitative study notes that the implementa-
tion of DOT is in the process of shifting from being a rigid model
involving observation of drug swallowing to one that includes an
array of incentives and enablers for supporting the patient (Macq
2003). Within such a package of patient-centred interventions it
remains to be established whether direct observation is necessary at
all. Of interest in this regard are the findings of a cluster-random-
ized trial in a rural South Africa in which motivation and support
from a lay health worker (with or without DOT) was shown to be
more effective in ensuring treatment than a conventional DOT-
based service (Clarke 2005). People with tuberculosis are often
poor and encounter numerous barriers to treatment adherence.
Strategies aimed at reducing social and health system barriers may
therefore be preferable to coercive approaches that impact nega-
tively on patient autonomy. The encouraging results of a recent
trial in Senegal using a multifaceted approach to address these
challenges, which also included a flexible approach to DOT, lend
support to this notion (Thiam 2007). Further rigorous trials, in
particular those testing interventions social and family barriers to
adherence, are needed (Garner 2007).
One of the trials included in our review found a modest im-
provementwithDOT for cure and treatment completion (Kamol-
ratanakul 1999), and one may speculate about the reasons for
these findings. The Thai health system is relatively well resourced
and has a tuberculosis control programme that is well organized.
This is in contrast to the trials in South Africa (Zwarenstein 1998;
Zwarenstein 2000) and Pakistan (Walley 2001) where the trials
were conducted in areas with high disease burden, overcrowded tu-
berculosis clinics, and poorly motivated staff. On the other hand,
DOT did not improve treatment completion rates in either Aus-
tralia (MacIntyre 2003) or the USA (Chaisson 2001; Malotte
2001), both of which are low burden, highly resourced settings.
A second reason one might posit is that cultural responses to su-
pervision may vary with Thai people being more responsive to
this approach. Finally, Kamolratanakul 1999 is so far the only trial
to have allowed participants to choose their supervisor, and this
patient-centred approach may also have influenced the effects.
Can adopting a DOT policy make adherence worse? The authors
of the South African trial suggest an increasingly negative and de-
moralizing effect of direct observation on participants with tuber-
culosis (Zwarenstein 1998). This trial found that in participants
with a first episode of tuberculosis, the outcomes were equivalent
in DOT and self administration of treatment arms, while ’retreat-
ment’ participants who were assigned to DOT fared worse than
those who self administered treatment. Given the small numbers
of participants in the retreatment group, further research is war-
ranted to confirm the findings.
Bias could have influenced the results in some of the trials. As
outlined in the methodological quality assessment, the number of
trials with adequate quality criteria was limited: four with adequate
method for concealing treatment allocation; four with blinding
of the outcome assessors; and two trials that excluded more than
10% of participants from the analysis. Nevertheless, these trials are
not easy to implement and are a credit to the researchers who have
worked hard to develop the evidence base for rational decision
making.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Randomized controlled trials provide no assurance that the routine
use of DOT in low- and middle-income countries improves cure
or treatment completion in people with tuberculosis. There is also
no rigorous evidence to support the use of DOT for prophylaxis
in people with latent tuberculosis.
There appears to be no sound reason to advocate the allocation of
resources to the routine use of DOT until we better understand
the situations in which it may be beneficial. In the meantime, it
could reasonably be argued that resources should be invested in
interventions that have been shown to be effective for improving
adherence, such as providing patient motivation and support, in-
centives, and defaulter action.
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Implications for research
The relation between DOT and treatment outcome is complex.
Factors that determine its usefulness in various settings require
further study. The extent to which the quality of interaction be-
tween patients and their observers influences outcome would be a
particularly fruitful topic for future research. It will also be worth
testing whether DOT efficacy differs in people receiving tubercu-
losis treatment for the first time compared with those requiring
retreatment, and in men compared with women. Comparisons of
DOT in relation to other strategies aimed at improving adherence
should be determined.
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T A B L E S
Characteristics of included studies
Study Chaisson 2001
Methods Generation of allocation sequence: randomized, with factorial overlay; computer-generated random numbers
Allocation concealment: not stated
Blinding: none
Completeness of follow up: 88%
Participants Number: 300 randomized; 73% men; 85% unemployed; 27% with documented HIV infection
Included: adult, intravenous drug users with positive tuberculin skin test (at least 10 mm induration or 5
mm if HIV positive); given isoniazid preventive therapy for 6 months
Excluded: people with active tuberculosis
Interventions (1) DOT twice weekly by outreach nurse at clinic or community location
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Characteristics of included studies (Continued )
(2) Daily self administration of treatment, monthly peer counselling group meetings with lunch, and clinical
assessments by a nurse; peer counsellor was a former injection user who had completed preventive therapy,
and who was trained in counselling and supervised by a health educator
(3) Daily self administration of treatment with monthly clinic assessment; factorial design with immediate or
deferred US$10 stipend at the end of each month; deferred payments credited each month and given when
treatment completed or participant withdrew
Outcomes (1) 6 months treatment completed, defined as 80% or more of treatments taken (observed for DOT group
and 6 monthly visits plus reporting that at least 80% medication taken during a month for other groups)
(2) Pill counts
(3) Isoniazid metabolites in the urine
(4) Electronically monitored bottle opening in a subset
Notes Location: Baltimore City Health Department TB Clinic, USA
Date: 1995-7
Duration of DOT duration not stated
Allocation concealment B – Unclear
Study Kamolratanakul 1999
Methods Generation of allocation sequence: central block random allocation scheme prepared for each of 15 study
sites; random-number table used
Allocation concealment: none
Blinding: no blinding of assessors
Completeness of follow up: 100% (no losses)
Participants Number: 837 randomized; 73% male
Included: new smear positive adults (aged 15+)
Interventions (1)Daily supervision: participants chose their supervisor from (a) health centre staff, (b) communitymembers,
or (c) familymembers; for (b) and (c) health workers visited homes twice monthly (first 2months) or monthly
for checking of treatment cards, pill counts, and urine tests
(2) Self administration of treatment: 1 month drug supply given at diagnosis and after each follow-up visit;
no treatment supervision between visits
All participants received the same drug regimen: isoniazid-rifampicin-pyrazinamide-ethambutol for 2months
and isoniazid-rifampicin for 4 months
Outcomes (1) Cure rate (primary outcome): completed 6 months antituberculous therapy, with 2 negative sputum
exams, 1 at end of treatment
(2) Treatment completion: completed 6 months antituberculous therapy but less than 2 sputum exams
(3) Sputum conversion rate: negative sputum at end of third month
(4) Percentage defaults
(5) Percentage transfers
(6) Caseholding rate
Notes Location: Thailand
Date: 1996-7
Duration of
DOT not stated
Informed consent not obtained as participants were not told that they were participating in a study
Choice of supervisor for DOT participants: 352 chose a family member; 34 chose a community member;
and 24 chose health centre staff
One participant in daily supervision arm excluded due to protocol violation so not strictly intention-to-treat
Allocation concealment C – Inadequate
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Characteristics of included studies (Continued )
Study Lwilla 2003
Methods Cluster-randomized controlled trial: 9 pairs of centres matched by type and size
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: none
Completeness of follow up: 87% at 2 months and 69% at 7 months
Participants Number: 18 clusters randomized; 522 participants; mean age 35; 60% male
Included: new smear positive adults
Interventions (1) Community-based DOT: daily observation by community health volunteer (site not stated) for intensive
2-month treatment period; health worker visited volunteer every 2 weeks and district co-ordinator visited
volunteer monthly; at each visit participants’ treatment card checked and drugs counted
(2) Institution-based DOT: required to attend health facility daily for 2 months, and then monthly after this
Continuation phase of 6 months: both groups managed the same and expected to self administer treatment
daily
Outcomes (1) Sputum negative at 2 months (primary outcome)
(2) Cure at 7 months (sputum negative at 2 months and at 5 to 7 months)
Notes Location: Tanzania
Date: 1999-2000
Duration of DOT not stated
Allocation concealment B – Unclear
Study MacIntyre 2003
Methods Quasi-randomized controlled trial
Generation of allocation sequence: alternate allocation
Concealment of allocation: none
Blinding: assessment of urinary isoniazid blinded
Completeness of follow up: not stated
Participants Number: 173 recruited, mostly foreign nationals; male 51%; mean age 41 (range 14 to 83)
Included: new tuberculosis participants
Excluded:multiple-drug resistant tuberculosis; relapsed tuberculosis;HIV-positive cases; and nontuberculous
mycobacterial infections
Interventions (1) Family-based DOT: daily observation by a nominated family member who received education and was
expected to record participant compliance with pill taking; weekly phone calls from a nurse; nurse on call;
nurse home visit every 2 weeks
(2) Self administration of treatment: daily
Both groups had monthly visits to health facilities and standardized recording charts
Outcomes Treatment completion measured by:
(1) Percentage clinic attendances to collect drugs
(2) Urinary isoniazid (6 random checks over months; all had to be > 0)
Notes Location: Australia
Date: 1998 to December 2000
Duration of DOT not stated
Allocation concealment C – Inadequate
Study Malotte 2001
Methods Generation of allocation sequence: randomized, blocks of 18
Allocation concealment: sequentially numbered, opaque, sealed envelopes
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Characteristics of included studies (Continued )
Blinding: none
Completeness of follow up: not stated
Participants Number: 163 randomized; 82% male
Included: active or recent injection or crack cocaine users screened for tuberculosis with positive tuberculin
skin test (at least 10 mm induration or 5 mm if HIV positive)
Excluded: people with active tuberculosis
Interventions (1) DOT by outreach worker (location decided by participant) plus US$5 at each visit
(2) As (1) but no money
(3) DOT at study community site plus US$5
All participants received isoniazid 2 times a week for 6 months or 1 year (depending on HIV status)
Outcomes (1) Percentage medication taken on time; excludes medication taken late (next day)
(2) Completion of medication
Notes Location: Long Beach, California, USA
Date: 1994-7
Lost to follow up included prison or moved and were included in outcome (1) but excluded completely from
outcome (2)
Allocation concealment A – Adequate
Study Newell 2006
Methods Cluster-randomized controlled trial
Generation of allocation sequence: 5 randomly selected districts allocated to each arm; the name of each
district was written on an individual paper and randomly drawn from a basket
Allocation concealment: method not stated
Blinding: laboratory technicians assessing the primary outcomes were blinded
Completeness of follow up: 100% (no clusters or individuals lost)
Participants Number: 10 districts with 907 people randomized; all smear positive; 67% male
Included: people with tuberculosis (aged 15+); new smear-positive cases, diagnosed at health facilities in the
study area; HIV-status not known
Interventions (1) Community-based DOT: daily treatment supervised by a female community health worker (unpaid
volunteer selected by the district health authority) or village health worker (community worker paid by
government). Patients mainly visited at home, but occasionally patients met their supervisor at her home.
Supervision was for the duration of treatment with drugs provided to the supervisor monthly. Tracing by the
supervisor was undertaken for patients who discontinued treatment
(2) Family-based DOT: daily supervision by a household member chosen by the participant with drugs
provided to the supervisory weekly. Government workers traced those who discontinued treatment
Outcomes (1) Treatment success: cure plus treatment completion [primary]
(2) Treatment success compared with the World Health Organization target of 85%
(3) Estimated case detection rate with the World Health Organization target of 70%
(4) Compare the above rates in men and women
Notes Location: hill and mountain districts of Nepal
Date: 2002-3
Allocation concealment C – Inadequate
Study Walley 2001
Methods Generation of allocation sequence: computer-generated random numbers
Allocation concealment: opaque, sealed envelopes
Blinding: assessors blinded
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Characteristics of included studies (Continued )
Completeness of follow up: not stated
Participants Number: 497 randomized; 51.3% male
Included: adults (aged 15+); new smear-positive cases
Interventions (1) DOT by a health worker at a health facility that met “access criteria” or a community health worker at
or near the participant’s home: access criteria were return journey from the participant’s home to facility <
2 km, < 2 h duration, and < 10 rupees, and for unmarried women an accompanying relative was available;
participants had to attend a health facility or meet a community health worker 6 times per week for 2 months
to take their drugs; thereafter they self administered drugs that the participants collected twice a month
(2) DOT by a family member chosen by the participant
(3) Self administration of drugs collected by participant fortnightly
All participants received isoniazid-rifampicin-pyrazinamide-ethambutol for 2 months and isoniazid-etham-
butol for 6 months
Outcomes (1) Cure: sputum negative at 7 or 8 months and on at least 1 previous occasion
(2) Treatment completion: treatment completed, but smear results not available on at least 2 occasions before
completion of treatment
(3) Treatment failure
(4) Death
(5) Default
(6) Transferred out
Notes Location: Pakistan
Date: 1996-8
Allocation concealment A – Adequate
Study Wandwalo 2004
Methods Generation of allocation sequence: coin tossing in each of 5 clinics
Allocation concealment: none
Blinding: none
Completeness of follow up: 100% (no losses)
Participants Number: 587 randomized; 322 smear positive, 182 smear negative, and 83 extrapulmonary tuberculosis;
57% male
Included: people with tuberculosis (aged 5+); new smear positive, smear negative, and extrapulmonary cases;
HIV-status not known
Excluded: previously treated for tuberculosis; severe illness; transferred fromanother clinic; previously enrolled
in the study
Interventions (1) Community-based DOT: daily treatment supervised at home by ’guardian’ (usually a family member)
during 2-month intensive period; supervisors trained to observe drug taking, encourage participants to
complete treatment, keep records, collect drugs, and assess drug side effects; during first 2months participants
received ’spot’ visits by health workers who conducted treatment card checks and pill counts; during first 2
months participants also requested to attend clinic every 2 weeks for clinical review and progress monitoring
(2) Health facility-based DOT: daily supervision at clinic by health workers during the 2 month intensive
period
Apart from the observation option participants received the same standardized management including drug
therapy
Outcomes (1) Treatment success: cure plus treatment completion
(2) Cure: smear positive initially and negative at 7 or 8 months and on at least 1 previous occasion
(3) Treatment completion: positive results initially, negative at 2 months and no results at end of treatment;
or smear negative initially and received treatment on clinical grounds; or those who completed full course of
treatment but had no initial or end-of-treatment results
(4) Death: from all causes
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(5) Treatment failure: participants who remained or became smear positive or 5 months or later
(6) Default: failed to collect medication for > 2 consecutive months
(7) Transferred out: transferred to a clinic in another area
Notes Location: Dar es Salaam, Tanzania
Date: 2001-3
Allocation concealment C – Inadequate
Study Wright 2004
Methods Generation of allocation sequence: unclear; stratified into adults and children; then, within each group,
randomized by type of tuberculosis (sputum positive, sputum negative, extrapulmonary, relapse)
Allocation concealment: unclear; sealed, sequentially numbered envelopes not stated if opaque
Blinding: assessors of sputum results blinded
Completeness of follow up: 98%
Participants Number: 1353 randomized; 55% male; most 15+ years
Included: adults and children with smear positive or negative, extrapulmonary tuberculosis, or relapse of
previously treated tuberculosis
Excluded: died before discharge; or too ill to receive outpatient treatment; lived in area without treatment
supporter; or referred in after treatment commenced
Interventions (1) DOT by community health worker: participants visited for observation daily; community health worker
trained to provide daily treatment supervision, record adherence on Treatment Support Card, remind partic-
ipants who did not report for treatment, and notify diagnostic centre about those who defaulted treatment
(2) DOT by family member: familymember or carer chosen by participant trained to provide daily treatment
supervision, record adherence on Treatment Support Card, and remind participants who did not report for
treatment; participants also required to visit the community health worker weekly to check side effects and
adherence and receive health education; defaulters reported to the diagnostic centre
Outcomes (1) Cure or treatment completion: cure defined as smear negative at 6 months and on at least 1 previous
occasion; treatment completion defined as treatment completed but smear results not available on at least 2
occasions before treatment completion
(2) Death
(3) Treatment failure: remained or became smear positive at > = 5 months
(4) Default: failed to collect medication for > 2 consecutive months
(5) Transferred out: formally transferred to another centre
Notes Location: Swaziland
Date: 2000-2
Allocation concealment B – Unclear
Study Zwarenstein 1998
Methods Generation of allocation sequence: computer-generated random numbers
Allocation concealment: consecutively numbered, opaque, sealed envelopes in each of 5 clinics
Blinding: none
Completeness of follow up: 114/120 (95%) in 1 trial and 102/120 (85%) in other trial excluded from analysis
Participants Number: 216 included in analysis; 62% male; 57% < 35 years
Included: adults (aged 15+) with pulmonary tuberculosis; both new and retreatment cases
Excluded: severe disease or multiple drug resistance; treatment at a non-study clinic for more than 2 weeks;
need to be supervised at school or at the workplace; and leaving the area within a month
Interventions (1) DOT by clinic nurses: participants asked to visit the clinic 5 days a week for 8 weeks (new participants) or
for 12 weeks (retreatment participants); thereafter expected attendance was 3 days a week for the continuation
phase; clinic visits restricted to normal working hours and adherence card signed and dated by a nurse at
each visit and kept at the clinic
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Characteristics of included studies (Continued )
(2) Self administration of treatment: participants had to visit clinic once a week or send a relative to collect
drugs; participants completed their own adherence card for every day of drug taking and a nurse recorded
the weekly drug collection; adherence card handed to nurse at the weekly clinic visit
New cases received Rifater (combined rifampicin-isoniazid-pyrazinamide) for 8 weeks followed by Rifinah
4 (combined rifampicin-isoniazid) plus additional isoniazid for 18 weeks
Retreatment participants received Rifater plus ethambutol for 12 weeks and Rifinah plus rifampicin-etham-
butol for 22 weeks
Outcomes (1) “Successful treatment” included those who were cured and those who completed treatment; “cured”
applied to those who converted from a positive smear and/or culture to a negative smear and/or culture at
the end of treatment (6 months for new participants and 8 months for retreatment participants); “treatment
completed” referred to participants who (a) completed the full course of treatment but had no pretreatment or
post-treatment bacteriological results; (b) had negative pretreatment results and had been treated on clinical
grounds; or (c) had positive pretreatment results, negative results after 2months and no post-treatment results
(2) “Treatment failure” applied to participants with a positive smear or culture at the end of treatment
(3) “Treatment interrupters” applied to participants who stopped taking treatment for 8 or more weeks
during the treatment period
(4) Transfer to another treatment facility
(5) Death from tuberculosis or other causes while on treatment
Notes Location: 1 trial in each of 2 low-income communities near Cape Town, South Africa
Date: 1994-5
Results combined
54 participants in 1 trial allocated to community supervision not reported in this paper
Exclusions from analysis: trial 1 (6 cases of multiple drug resistance) and trial 2 (12 cases of multiple drug
resistance and 6 not tuberculosis)
Number of exclusions per arm of the 2 trials not given
Allocation concealment A – Adequate
Study Zwarenstein 2000
Methods Generation of allocation sequence: computer-generated random numbers
Allocation concealment: consecutively numbered, opaque, sealed envelopes
Blinding: none
Completeness of follow up: not stated
Participants Number: 174 randomized
Included: new or retreatment participants aged 15+ who were sputum or culture positive
Interventions (1) DOT by clinic nurses (see Zwarenstein 1998)
(2) Self administration (see Zwarenstein 1998)
(3) DOT by lay health workers: participants took drugs at home of a lay health worker under supervision;
if participant missed treatment for 1 day, a lay health worker visited participant’s home and if necessary a
member of the South African Tuberculosis Association (SANTA) also visited the participant
Outcomes As for Zwarenstein 1998
Notes Location: 4 clinics in a township near Cape Town, South Africa
Date: 1994-5
18 participants excluded from analysis: 12 with multiple-drug resistant tuberculosis and 6 not tuberculosis
Allocation concealment A – Adequate
DOT: directly observed therapy; HIV: human immunodeficiency virus
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Characteristics of excluded studies
Study Reason for exclusion
Batki 2001 Compared direct observation plus with methadone treatment for injecting drug users with routine tuberculosis
treatment without methadone
Carroll 2004 Before-and-after study; no control group
Hwang 2004 Not randomized
Jasmer 2004 Different criteria for allocation to self administration or direct observation
Lewin 2004 An educational intervention was evaluated
Mathew 2002 Cohort study
Moulding 2001 Trial evaluating devices that monitor treatment using uranium along a strip of photographic film
Pungrassami 2002 2 publications reporting the same study; not randomly allocated
Sorete-Abore 2002 Cohort study
Tandon 2002 Described as a randomized trial, but the randomization led to very different numbers in the 2 groups; subsequently
over 50 participants (out of a total of 379) crossed over from self treatment to direct observation and were excluded
from the analysis; little detail for the rest of the study provided
Thiam 2007 Multifaceted intervention including directly observed therapy
Toyota 2003 Patients in hospital
A D D I T I O N A L T A B L E S
Table 01. Search strategies for databases
Search set CIDG SRˆ CENTRAL MEDLINEˆˆ EMBASEˆˆ LILACSˆˆ
1 tuberculosis tuberculosis tuberculosis tuberculosis tuberculosis
2 DOT* PATIENT
COMPLIANCE
PATIENT
COMPLIANCE
PATIENT
COMPLIANCE
DOT*
3 directly observed
therapy
PATIENT
PARTICIPATION
PATIENT
PARTICIPATION
PATIENT
MONITORING
supervision
4 2 or 3 patient monitoring MOTIVATION DOT$ 2 or 3
5 1 and 4 MOTIVATION DECISION SUPPORT
TECHNIQUES
directly observed
therapy
1 and 4
6 - DECISION SUPPORT
TECHNIQUES
DOT* compliance -
7 - DOT* directly observed
therapy
motivation -
8 - directly observed
therapy
compliance patient$ -
9 - compliance patient* defaulter$ -
10 - defaulter* defaulter* adheren$ -
11 - adheren* adheren* supervis$ -
17Directly observed therapy for treating tuberculosis (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Table 01. Search strategies for databases (Continued )
Search set CIDG SRˆ CENTRAL MEDLINEˆˆ EMBASEˆˆ LILACSˆˆ
12 - supervision* supervis* 2-11/or -
13 - 2-12/or 2-12/or 1 and 12 -
14 - 1 and 13 1 and 13 Limit 13 to human -
15 - - Limit 14 to human - -
ˆCochrane Infectious
Diseases Group
Specialized Register
ˆˆSearch terms used
in combination with
the search strategy
for retrieving trials
developed by The
Cochrane Collaboration
(Higgins 2006);
upper case: MeSH or
EMTREE heading;
lower case: free text term
Table 02. Methodological quality assessmentˆ
Trial Randomization type Sequenceˆˆ Concealmentˆˆ Blinding (assessors) Completenessˆˆ
Chaisson 2001 Individual Adequate Unclear Inadequate Inadequate
Kamolratanakul 1999 Individual Adequate Inadequate Inadequate Adequate
Lwilla 2003 Cluster Unclear Unclear Inadequate Inadequate
MacIntyre 2003 Individual Inadequate Inadequate Adequate Unclear
Malotte 2001 Individual Unclear Adequate Inadequate Unclear
Newell 2006 Cluster Adequate Inadequate Adequate Adequate
Walley 2001 Individual Adequate Adequate Adequate Unclear
Wandwalo 2004 Individual Adequate Inadequate Inadequate Adequate
Wright 2004 Individual Unclear Unclear Adequate Adequate
Zwarenstein 1998 Individual Adequate Adequate Inadequate Adequate
Zwartenstein 2000 Individual Adequate Adequate Inadequate Unclear
ˆDetails of methods
in the ’Characteristics
of included studies’;
ˆˆGeneration of
allocation sequence,
allocation concealment,
and completeness of
follow up
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A N A L Y S E S
Comparison 01. Direct observation versus self administration
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Cure 4 1603 Relative Risk (Random) 95% CI 1.02 [0.86, 1.21]
02 Cure or completion of
treatment
4 1603 Relative Risk (Fixed) 95% CI 1.06 [1.00, 1.13]
03 Completion of treatment Relative Risk (Fixed) 95% CI Totals not selected
Comparison 02. Direct observation versus self administration: stratified by location of direct observation
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Cure Relative Risk (Fixed) 95% CI Subtotals only
02 Cure or completion of
treatment
Relative Risk (Fixed) 95% CI Subtotals only
Comparison 03. Direct observation: home versus clinic
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Cure or completion of
treatment
Relative Risk (Fixed) 95% CI Totals not selected
Comparison 04. Home-based direct observation: family member versus community health worker
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Cure or completion of
treatment
Relative Risk (Fixed) 95% CI Totals not selected
Comparison 05. Intravenous drug users: direct observation versus self administration
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Completion of treatment Relative Risk (Fixed) 95% CI Totals not selected
Comparison 06. Intravenous drug users: choose own location versus treatment centre
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Completion of treatment Relative Risk (Fixed) 95% CI Totals not selected
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antitubercular Agents [∗therapeutic use]; ∗Directly Observed Therapy; Randomized Controlled Trials as Topic; Tuberculosis, Pul-
monary [∗drug therapy]
MeSH check words
Humans
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 Direct observation versus self administration, Outcome 01 Cure
Review: Directly observed therapy for treating tuberculosis
Comparison: 01 Direct observation versus self administration
Outcome: 01 Cure
Study DOT Self Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Kamolratanakul 1999 315/414 283/422 41.5 1.13 [ 1.04, 1.24 ]
Walley 2001 199/335 100/162 34.2 0.96 [ 0.83, 1.12 ]
Zwarenstein 1998 18/53 31/61 11.2 0.67 [ 0.43, 1.05 ]
Zwarenstein 2000 55/112 18/44 13.1 1.20 [ 0.80, 1.79 ]
Total (95% CI) 914 689 100.0 1.02 [ 0.86, 1.21 ]
Total events: 587 (DOT), 432 (Self)
Test for heterogeneity chi-square=8.41 df=3 p=0.04 I² =64.3%
Test for overall effect z=0.21 p=0.8
0.2 0.5 1 2 5
Favours self Favours DOT
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Analysis 01.02. Comparison 01 Direct observation versus self administration, Outcome 02 Cure or
completion of treatment
Review: Directly observed therapy for treating tuberculosis
Comparison: 01 Direct observation versus self administration
Outcome: 02 Cure or completion of treatment
Study DOT Self Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Kamolratanakul 1999 347/414 320/422 59.8 1.11 [ 1.03, 1.18 ]
Walley 2001 216/335 105/162 26.7 0.99 [ 0.87, 1.14 ]
Zwarenstein 1998 27/53 37/61 6.5 0.84 [ 0.60, 1.17 ]
Zwarenstein 2000 73/112 26/44 7.0 1.10 [ 0.83, 1.46 ]
Total (95% CI) 914 689 100.0 1.06 [ 1.00, 1.13 ]
Total events: 663 (DOT), 488 (Self)
Test for heterogeneity chi-square=4.25 df=3 p=0.24 I² =29.4%
Test for overall effect z=1.80 p=0.07
0.5 0.7 1 1.5 2
Favours self Favours DOT
Analysis 01.03. Comparison 01 Direct observation versus self administration, Outcome 03 Completion of
treatment
Review: Directly observed therapy for treating tuberculosis
Comparison: 01 Direct observation versus self administration
Outcome: 03 Completion of treatment
Study DOT Self Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
MacIntyre 2003 84/87 78/86 1.06 [ 0.98, 1.15 ]
0.5 0.7 1 1.5 2
Favours self Favours DOT
22Directly observed therapy for treating tuberculosis (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Analysis 02.01. Comparison 02 Direct observation versus self administration: stratified by location of direct
observation, Outcome 01 Cure
Review: Directly observed therapy for treating tuberculosis
Comparison: 02 Direct observation versus self administration: stratified by location of direct observation
Outcome: 01 Cure
Study DOT Self Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Direct observation at home
Kamolratanakul 1999 315/414 283/422 66.0 1.13 [ 1.04, 1.24 ]
Walley 2001 161/269 100/162 29.4 0.97 [ 0.83, 1.13 ]
Zwarenstein 2000 31/54 18/44 4.7 1.40 [ 0.92, 2.14 ]
Subtotal (95% CI) 737 628 100.0 1.10 [ 1.02, 1.18 ]
Total events: 507 (DOT), 401 (Self)
Test for heterogeneity chi-square=4.30 df=2 p=0.12 I² =53.4%
Test for overall effect z=2.45 p=0.01
02 Direct observation at clinic
Walley 2001 38/66 100/162 53.5 0.93 [ 0.73, 1.19 ]
Zwarenstein 1998 42/111 49/105 46.5 0.81 [ 0.59, 1.11 ]
Subtotal (95% CI) 177 267 100.0 0.88 [ 0.72, 1.06 ]
Total events: 80 (DOT), 149 (Self)
Test for heterogeneity chi-square=0.50 df=1 p=0.48 I² =0.0%
Test for overall effect z=1.34 p=0.2
0.2 0.5 1 2 5
Favours self Favours DOT
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Analysis 02.02. Comparison 02 Direct observation versus self administration: stratified by location of direct
observation, Outcome 02 Cure or completion of treatment
Review: Directly observed therapy for treating tuberculosis
Comparison: 02 Direct observation versus self administration: stratified by location of direct observation
Outcome: 02 Cure or completion of treatment
Study DOT self Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Direct observation at home
Kamolratanakul 1999 347/414 320/422 66.5 1.11 [ 1.03, 1.18 ]
Walley 2001 176/269 105/162 27.5 1.01 [ 0.88, 1.16 ]
Zwarenstein 1998 40/54 26/44 6.0 1.25 [ 0.94, 1.68 ]
Subtotal (95% CI) 737 628 100.0 1.09 [ 1.02, 1.16 ]
Total events: 563 (DOT), 451 (self)
Test for heterogeneity chi-square=2.17 df=2 p=0.34 I² =7.6%
Test for overall effect z=2.64 p=0.008
02 Direct observation at clinic
Walley 2001 40/66 105/162 48.4 0.94 [ 0.75, 1.17 ]
Zwarenstein 1998 60/111 63/105 51.6 0.90 [ 0.71, 1.14 ]
Subtotal (95% CI) 177 267 100.0 0.92 [ 0.78, 1.08 ]
Total events: 100 (DOT), 168 (self)
Test for heterogeneity chi-square=0.05 df=1 p=0.82 I² =0.0%
Test for overall effect z=1.04 p=0.3
0.5 0.7 1 1.5 2
Favours self Favours DOT
Analysis 03.01. Comparison 03 Direct observation: home versus clinic, Outcome 01 Cure or completion of
treatment
Review: Directly observed therapy for treating tuberculosis
Comparison: 03 Direct observation: home versus clinic
Outcome: 01 Cure or completion of treatment
Study Home Clinic Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
Wandwalo 2004 221/260 271/327 1.03 [ 0.96, 1.10 ]
0.5 0.7 1 1.5 2
Favours clinic Favours home
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Analysis 04.01. Comparison 04 Home-based direct observation: family member versus community health
worker, Outcome 01 Cure or completion of treatment
Review: Directly observed therapy for treating tuberculosis
Comparison: 04 Home-based direct observation: family member versus community health worker
Outcome: 01 Cure or completion of treatment
Study Family member Health worker Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
Wright 2004 440/662 453/664 0.97 [ 0.90, 1.05 ]
0.5 0.7 1 1.5 2
Favours worker Favours family
Analysis 05.01. Comparison 05 Intravenous drug users: direct observation versus self administration,
Outcome 01 Completion of treatment
Review: Directly observed therapy for treating tuberculosis
Comparison: 05 Intravenous drug users: direct observation versus self administration
Outcome: 01 Completion of treatment
Study DOT Self Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
Chaisson 2001 80/99 79/100 1.02 [ 0.89, 1.18 ]
0.5 0.7 1 1.5 2
Favours self Favours DOT
Analysis 06.01. Comparison 06 Intravenous drug users: choose own location versus treatment centre,
Outcome 01 Completion of treatment
Review: Directly observed therapy for treating tuberculosis
Comparison: 06 Intravenous drug users: choose own location versus treatment centre
Outcome: 01 Completion of treatment
Study Own location Treatment centre Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
Malotte 2001 28/53 33/55 0.88 [ 0.63, 1.23 ]
0.5 0.7 1 1.5 2
Favours centre Favours own choice
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